Huiping Qiang1, Qing Chang1, Jianlin Xu1, Jialin Qian1, Yanwei Zhang1, Yuqiong Lei1, Baohui Han2, Tianqing Chu3. 1. Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Huaihai West Road No. 241, Shanghai, 200030, People's Republic of China. 2. Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Huaihai West Road No. 241, Shanghai, 200030, People's Republic of China. hanxkyy@aliyun.com. 3. Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Huaihai West Road No. 241, Shanghai, 200030, People's Republic of China. tianqing_chu@126.com.
Abstract
PURPOSE: Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182-1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment (TME). Some antiangiogenic therapies combined with chemotherapy, targeted therapy or immunotherapy have been approved for clinical application. In this review, we summarize the recent advances of antiangiogenic combination therapeutic strategies in advanced NSCLC. METHODS: References of this review are searched through PubMed and EMBASE and the abstracts of cancer conferences. The ClinicalTrials.gov database was used for relative trials. RESULTS: Based on different mechanisms, antiangiogenic agents can be divided into monoclonal antibodies (mAbs), which mainly include bevacizumab and ramucirumab, and multi-target antiangiogenic tyrosine kinase inhibitors (TKIs) which include sunitinib, sorafenib, nintedanib, apatinib, anlotinib, fruquintinib, etc. In recent years, a number of large clinical studies have shown that antiangiogenic agents have conferred a significant overall survival (OS) benefit to patients with advanced non-small cell lung cancer (NSCLC). More and more evidences confirm that the combination of antiangiogenic agents with chemotherapy, targeted therapy and immunotherapy can improve the effect and prolong the survival of NSCLC patients. However, many problems about the application of antiangiogenic agents on advanced NSCLC patients still need to be explored. For example, the combination therapy of multi-target antiangiogenic agents is just beginning, and the biomarkers are not clear. CONCLUSIONS: Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
PURPOSE:Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182-1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment (TME). Some antiangiogenic therapies combined with chemotherapy, targeted therapy or immunotherapy have been approved for clinical application. In this review, we summarize the recent advances of antiangiogenic combination therapeutic strategies in advanced NSCLC. METHODS: References of this review are searched through PubMed and EMBASE and the abstracts of cancer conferences. The ClinicalTrials.gov database was used for relative trials. RESULTS: Based on different mechanisms, antiangiogenic agents can be divided into monoclonal antibodies (mAbs), which mainly include bevacizumab and ramucirumab, and multi-target antiangiogenic tyrosine kinase inhibitors (TKIs) which include sunitinib, sorafenib, nintedanib, apatinib, anlotinib, fruquintinib, etc. In recent years, a number of large clinical studies have shown that antiangiogenic agents have conferred a significant overall survival (OS) benefit to patients with advanced non-small cell lung cancer (NSCLC). More and more evidences confirm that the combination of antiangiogenic agents with chemotherapy, targeted therapy and immunotherapy can improve the effect and prolong the survival of NSCLCpatients. However, many problems about the application of antiangiogenic agents on advanced NSCLCpatients still need to be explored. For example, the combination therapy of multi-target antiangiogenic agents is just beginning, and the biomarkers are not clear. CONCLUSIONS: Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLCpatients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
Authors: Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Maria Q Baggstrom; Mark A Socinski; Xiaofei F Wang; Lin Gu; Thomas E Stinchcombe; Martin J Edelman; Sherman Baker; Josephine Feliciano; Paul Novotny; Olwen Hahn; Jeffrey A Crawford; Everett E Vokes Journal: J Thorac Oncol Date: 2017-02-01 Impact factor: 15.609
Authors: Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol Journal: Lancet Date: 2014-06-02 Impact factor: 79.321
Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: Renata A de Abrantes; Tatianne M Batista; Vivianne M Mangueira; Tatyanna K G de Sousa; Rafael C Ferreira; Ana Paula G Moura; Lucas S Abreu; Adriano F Alves; Eudes S Velozo; Leônia M Batista; Marcelo S da Silva; Josean F Tavares; Marianna V Sobral Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2021-12-02 Impact factor: 3.000
Authors: Rosanna Sestito; Roberta Cianfrocca; Piera Tocci; Laura Rosanò; Andrea Sacconi; Giovanni Blandino; Anna Bagnato Journal: Commun Biol Date: 2020-11-13